The impact of COVID-19 on rare metabolic patients and healthcare providers: results from two MetabERN surveys
Abstract The ongoing coronavirus disease 2019 (COVID-19) pandemic has caused disruption in all aspects of daily life, including the management and treatment of rare inherited metabolic disorders (IMDs). To perform a preliminary assessment of the incidence of COVID-19 in IMD patients and the impact o...
Main Authors: | C. Lampe, C. Dionisi-Vici, C. M. Bellettato, L. Paneghetti, C. van Lingen, S. Bond, C. Brown, A. Finglas, R. Francisco, S. Sestini, J. M. Heard, M. Scarpa, MetabERN collaboration group |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-12-01
|
Series: | Orphanet Journal of Rare Diseases |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13023-020-01619-x |
Similar Items
-
Research activity and capability in the European reference network MetabERN
by: Jean-Michel Heard, et al.
Published: (2019-05-01) -
Social and medical needs of rare metabolic patients: results from a MetabERN survey
by: Sylvia Sestini, et al.
Published: (2021-08-01) -
Availability, accessibility and delivery to patients of the 28 orphan medicines approved by the European Medicine Agency for hereditary metabolic diseases in the MetabERN network
by: Jean-Michel Heard, et al.
Published: (2020-01-01) -
Challenges in Transition From Childhood to Adulthood Care in Rare Metabolic Diseases: Results From the First Multi-Center European Survey
by: Karolina M. Stepien, et al.
Published: (2021-02-01) -
U-IMD: the first Unified European registry for inherited metabolic diseases
by: Thomas Opladen, et al.
Published: (2021-02-01)